Oswal Pumps Commits ₹456 Crore to 1.2 GW TOPCon Solar Cells
Domestic cell rules are pushing India's module assemblers upstream, and some are funding the move by rewriting promises made to IPO investors.
Oswal Pumps will build 1.2 GW of TOPCon solar cell capacity at an estimated cost of ₹456 crore, with commercial production targeted for April 2028. The company's board approved the plant through its wholly owned subsidiary, Oswal Solar Energy Pvt Ltd (OSEPL). PV Magazine India reported the approval on 14 October, citing company disclosures.
ALMM List-II Turns Cell Supply Into the Binding Constraint
For most Indian module makers, cells have been the easiest input to import and the hardest to source locally. That arithmetic changes once the Approved List of Models and Manufacturers covers cells. Oswal describes ALMM List-II as now in force. Under it, projects with domestic content obligations must use approved Indian cells as well as approved modules.
Oswal sits squarely inside that obligation. Its core solar pump business depends on government-backed programmes such as PM-KUSUM, which require domestic content requirement (DCR) cells. The company says the plant will secure approved domestic cells for its own module lines and shield it from swings in open-market cell pricing.
Debt and Diverted IPO Capital Fund the Plant
About ₹296 crore of the project cost will be raised as debt. The remaining ₹159.85 crore will come from ₹163.04 crore of unspent IPO proceeds, originally earmarked for an aluminium frame facility, 300 MW of EVA encapsulant capacity and the outstanding 500 MW of a module facility. Only ₹3.19 crore of the unspent pool remains uncommitted. Oswal aims to deploy the funds on the cell plant by FY2028.
At full capacity, the line will meet roughly 75% of OSEPL's cell demand, and the balance will still be bought externally. OSEPL runs 570 MW of module capacity today and has a further 1 GW under construction.
Oswal Trades Three Component Projects for One Cell Bet
The reallocation is the more revealing disclosure. Oswal is abandoning three lower-barrier component projects in favour of one capital-intensive position in cells, the segment where DCR rules create scarcity. The implicit judgement is that margins on approved cells will outweigh the cost of buying frames and encapsulant from third parties.
That logic favours vertically integrated manufacturers over pure module assemblers, which will compete for a limited pool of approved domestic cells until new lines come online. Chairman and Managing Director Vivek Gupta framed the case in operational terms: "Bringing cell manufacturing in-house gives us greater control over quality, cost and timelines."
Two caveats temper the strategy. A TOPCon line still runs on wafers, which India largely imports, so Oswal's supply risk moves upstream rather than disappearing. The plant also produces nothing until April 2028, leaving roughly 18 months of DCR cell purchases in a tight market.
What to Watch
Varying the stated objects of an IPO requires a special resolution of shareholders under Section 27 of the Companies Act, 2013. The first test is that vote, and how institutional holders respond to a capital plan that departs from the prospectus.
The 75% coverage figure implies a module base of about 1.6 GW, which depends on the 1 GW expansion finishing on schedule. Delays there would leave the cell line oversized relative to its own demand.
Beyond Oswal, track whether other module assemblers announce cell capacity or redirect capital in the same way. If they do, India's DCR cell shortage could ease by 2028, at the cost of slower investment in frames, encapsulants and other components.
For more climate news click here